top of page

Would you like to get rid of fine lines and wrinkles? Take a look at Xeomin (pronounced zeo - min). Xeomin is the purest form of botulinum toxin type A which is similar to the commonly known brand Botox. 

Xeomin is FDA approved for the treatment of frown lines and has over 10 years of success stories. Go ahead and schedule your free consultation today. 

See the Results

How Xeomin Works

This brief video shows the process of how Xeomin works to relax facial muscles and reduce wrinkles.

This detailed video demonstrates the mechanism that Xeomin uses to relax the muscles of the face which reduces wrinkles.

How Xeomin is Purified

XTRACT TechnologyTM is the only state-of-the-art manufacturing process that uniquely purifies the molecule removing the unnecessary proteins, leaving just the active therapeutic component.*


Botulinum toxin type A
is produced from Hall
strain Clostridium
botulinum serotype A1


proteins are
separated by

Molecule_XEOMIN_3 (1).png

Producing a
unique, purified

*The direct impact of the non-therapeutic proteins on long term safety or efficacy has not been established. Information about the unique XEOMIN manufacturing process and the properties of incobotulinumtoxinA is not intended to imply superiority over other botulinum toxin type A products.

Clinical Resistance Study

Of the 1490 patients treated with XEOMIN in placebo-controlled clinical trials across all indications, no patients demonstrated clinical resistance or secondary treatment failure due to NAb1†

Low Clinical Resistance Study

XEOMIN Has a Molecular Weight of 150 kDa

Molecule_XEOMIN_3 (1).png
  • The proprietary manufacturing process of XEOMIN isolates the active neuromodulator from the accessory proteins and reduces the number of proteins1-3

  • XEOMIN is formulated to have high biological activity with a low protein load1-3


Xeomin Manufacturing Video

  • The direct impact of the non-therapeutic proteins on long term safety or efficacy has not been established. Information about the unique XEOMIN manufacturing process and the properties of incobotulinumtoxinA is not intended to imply superiority over other botulinum toxin type A products

  • The potency Units of XEOMIN are specific to the preparation and assay method used and are not interchangeable with other preparations of botulinum toxin products. Therefore, Units of biological activity of XEOMIN cannot be compared to or converted into Units of any other botulinum toxin products

Frequently Asked Questions


Xeomin® (incobotulinumtoxinA) is a prescription medication injected into muscles and used to temporarily improve the appearance of moderate to severe frown lines between the eyebrows (glabellar lines) in adults. Xeomin® contains botulinum toxin type A, a protein purified from the bacterium Clostridium botulinum.


When you squint or frown, the muscles between your eyebrows contract, causing the skin to furrow and fold. Over time, as your skin ages and loses some of its elasticity, these repeated contractions can cause persistent frown lines. Botulinum toxin type A – the active ingredient in Xeomin®– acts on nerve endings in muscles to prevent muscle fibers from contracting. By reducing these contractions, Xeomin® can temporarily reduce the lines between your eyebrows.


Xeomin® was proven effective in two randomized, double-blind, multicenter, placebo-controlled clinical trials of 547 healthy, adult patients. The average age of patients in the study was 46 years. Patients received 20 Units of Xeomin® and were classified as responders if they had a 2-grade improvement on a 4-point scale as assessed by the physician and patient. Using these criteria, treatment success was higher with Xeomin® than placebo on Day 30 in both studies (60% and 48% vs. 0% for placebo in both studies). Based on these trials, Xeomin® received FDA approval for use in glabellar lines in 2011.


If you are an adult with moderate to severe glabellar lines, Xeomin® may be right for you. Talk to your doctor to discuss the benefits and risks of treatment. Do not use Xeomin® if you are allergic to botulinum toxin or any of the other ingredients in Xeomin®. You should also not use Xeomin® if you have had an allergic reaction to any other botulinum toxin product or have a skin infection at the planned injection site.


Before receiving treatment with Xeomin®, you should tell your doctor about all of your medical conditions, including whether you have a disease that affects your muscles and nerves, have allergies to any botulinum toxin product, or have experienced any side effect from any other botulinum toxin in the past. In addition, tell your doctor about your medical history and all the medicines you take, including prescription and nonprescription medicines, vitamins, and herbal supplements. Especially tell your doctor if you have received any other botulinum toxin product in the last four months or in the past. Be sure your doctor knows exactly which product(s) you received and when you received them.


During treatment, which usually takes about 10-20 minutes, your doctor will inject Xeomin® into the muscles in your forehead that cause frown lines between your eyebrows. No anesthesia is required; however, your physician may use a topical anesthetic or cold pack to reduce any discomfort.


You may begin to see visible smoothing as early as 3-4 days after injection. The median first onset of effect was less than a week. The maximum effect occurred at 30 days. The typical duration of effect was up to 3 months in clinical trials but may last significantly longer or shorter in individual patients.


Xeomin® may cause serious side effects, including allergic reactions. Symptoms of an allergic reaction to Xeomin® may include: itching, rash, redness, swelling, wheezing, asthma symptoms, or dizziness or feeling faint. Tell your doctor or seek medical help right away if you have wheezing, experience other asthma symptoms, or if you become dizzy or faint.In clinical trials of Xeomin® for the treatment of frown lines between the eyebrows, headache was the most common side effect. Xeomin® may cause loss of strength or general muscle weakness, blurred vision, or drooping eyelids within hours to weeks of taking Xeomin®. If this happens, do not drive a car, operate machinery, or do other dangerous activities. Tell your doctor if you have any side effect that bothers you or that does not subside. These are not all of the possible side effects of Xeomin®. For more information, see accompanying Important Safety InformationMedication Guide, and Full Prescribing Information, or ask your doctor.


Looking plastic or overdone is a common concern among individuals considering an in-office treatment for moderate to severe frown lines.* Talk to your licensed, trained, healthcare professional. There are steps you can take to make you feel more comfortable. First, have a detailed discussion with your provider. You want to talk through every concern you have, until you feel comfortable. Your provider, who is experienced in facial anatomy, can determine the right options for you. For example, the most widely used procedure for moderate to severe frown lines is neurotoxin injections, a class of prescription medication that has been shown to be effective in many studies. Finally, ask for an FDA-approved product, such as Xeomin®. Individual results may vary.


  1. XEOMIN® [Package insert]. Raleigh, NC: Merz Pharmaceuticals, LLC; 2019.

  2. Dressler D, Benecke R. Pharmacology of therapeutic botulinum toxin preparations. Disabil Rehabil. 2007;29(23):1761-1768.

  3. Dressler D. Botulinum toxin drugs: future developments. J Neural Transm. 2008;115(4):575-577.



XEOMIN® (incobotulinumtoxinA) for injection is indicated for the treatment of:

  • Chronic sialorrhea in adults

  • Upper limb spasticity in adults

  • Upper limb spasticity in pediatric patients 2 years of age and older, excluding spasticity caused by cerebral palsy

  • Cervical dystonia in adults

  • Blepharospasm in adults

See full prescribing information for complete BOXED WARNING.

The effects of XEOMIN and all botulinum toxin products may spread from the area of injection to produce symptoms consistent with botulinum toxin effects. These symptoms have been reported hours to weeks after injection. Swallowing and breathing difficulties can be life threatening and there have been reports of death. The risk of symptoms is probably greatest in children treated for spasticity but symptoms can also occur in adults, particularly in those patients who have underlying conditions that would predispose them to these symptoms.


  • Known hypersensitivity to any botulinum toxin product or to any of the components in the formulation.

  • Infection at the proposed injection site(s) because it could lead to severe local or disseminated infection.


  • The potency units of XEOMIN are specific to the preparation and assay method used and are not interchangeable with other preparations of botulinum toxin products. Therefore, Units of biological activity of XEOMIN cannot be compared to or converted into Units of any other botulinum toxin products.

  • Serious hypersensitivity reactions have been reported with botulinum toxin products (anaphylaxis, serum sickness, urticaria, soft tissue edema, and dyspnea). If serious and/or immediate hypersensitivity reactions occur, discontinue further injection of XEOMIN and institute appropriate medical therapy immediately. The use of XEOMIN in patients with a known hypersensitivity to any botulinum neurotoxin or to any of the excipients (human albumin, sucrose), could lead to a life-threatening allergic reaction.

  • Treatment with XEOMIN and other botulinum toxin products can result in swallowing or breathing difficulties. Patients with pre-existing swallowing or breathing difficulties may be more susceptible to these complications. When distant effects occur, additional respiratory muscles may be involved. Patients may require immediate medical attention should they develop problems with swallowing, speech, or respiratory disorders. Dysphagia may persist for several months, which may require use of a feeding tube. Aspiration may result from severe dysphagia [See BOXED WARNING].

  • Individuals with peripheral motor neuropathic diseases, amyotrophic lateral sclerosis, or neuromuscular junctional disorders (e.g., myasthenia gravis or Lambert-Eaton syndrome) may be at increased risk for severe dysphagia and respiratory compromise from typical doses of XEOMIN.

  • Cervical Dystonia: Treatment with botulinum toxins may weaken neck muscles that serve as accessory muscles of ventilation. This may result in critical loss of breathing capacity in patients with respiratory disorders who may have become dependent upon these accessory muscles. There have been post-marketing reports of serious breathing difficulties, including respiratory failure, in patients with cervical dystonia treated with botulinum toxin products. Patients with smaller neck muscle mass and patients who require bilateral injections into the sternocleidomastoid muscles are at greater risk of dysphagia. Limiting the dose injected into the sternocleidomastoid muscle may decrease the occurrence of dysphagia.

  • Blepharospasm: Injection of XEOMIN into the orbicularis oculi muscle may lead to reduced blinking and corneal exposure with possible ulceration or perforation. To decrease the risk for ectropion, XEOMIN should not be injected into the medial lower eyelid area.

  • XEOMIN contains human serum albumin. Based on effective donor screening and product manufacturing processes, it carries an extremely remote risk for transmission of viral diseases and variant Creutzfeldt-Jakob disease (vCJD). There is a theoretical risk for transmission of Creutzfeldt-Jakob disease (CJD), but if that risk actually exists, the risk of transmission would also be considered extremely remote. No cases of transmission of viral diseases, CJD, or vCJD have ever been reported for albumin.


The most commonly observed adverse reactions at rates specified below and greater than placebo are:

  • Chronic Sialorrhea in adults: (≥4% of patients) tooth extraction, dry mouth, diarrhea, and hypertension.

  • Upper Limb Spasticity in adults: (≥2% of patients) seizure, nasopharyngitis, dry mouth, upper respiratory tract infection.

  • Upper Limb Spasticity in pediatric patients: (≥3% of patients) nasopharyngitis and bronchitis.

  • Cervical Dystonia in adults: (≥5% of patients) dysphagia, neck pain, muscle weakness, injection site pain, and musculoskeletal pain.

  • Blepharospasm in adults: (≥10% of patients) eyelid ptosis, dry eye, visual impairment, and dry mouth.


Co-administration of XEOMIN and aminoglycoside or other agents interfering with neuromuscular transmission, (e.g., muscle relaxants), should only be performed with caution as these agents may potentiate the effect of the toxin.

Use of anticholinergic drugs after administration of XEOMIN may potentiate systemic anticholinergic effects.

The effect of administering different botulinum toxin products at the same time or within several months of each other is unknown. Excessive neuromuscular weakness may be exacerbated by administration of another botulinum toxin prior to the resolution of the effects of a previously administered botulinum toxin.


There are no adequate data on the developmental risk associated with the use of XEOMIN in pregnant women. XEOMIN should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.


Safety and effectiveness of XEOMIN in patients less than 18 years of age have not been established for lower limb spasticity, sialorrhea, cervical dystonia, or blepharospasm or for upper limb spasticity patients less than 2 years of age.

Safety and effectiveness have been established in pediatric patients 2 to 17 years of age in patients with upper limb spasticity. A pediatric assessment for XEOMIN demonstrates that XEOMIN is safe and effective in another pediatric population. However, XEOMIN is not approved for such patient population due to marketing exclusivity for another botulinum toxin.

bottom of page